{"id":"cefazolin-bacitracin-cefalexin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity/allergic reaction"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nephrotoxicity (bacitracin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin and cefalexin are cephalosporins that cross-link peptidoglycan in the bacterial cell wall, while bacitracin inhibits cell wall precursor transport. Together, they provide broad-spectrum bactericidal activity against gram-positive and some gram-negative bacteria. This combination approach may enhance coverage or reduce resistance development.","oneSentence":"This is a combination of three beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:10.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (specific indication unclear from phase 3 context)"}]},"trialDetails":[{"nctId":"NCT01628666","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-12","conditions":"Arrhythmia","enrollment":12814},{"nctId":"NCT01613092","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2011-05","conditions":"Arrhythmia","enrollment":241},{"nctId":"NCT01002911","phase":"PHASE3","title":"Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2009-12","conditions":"Arrythmias","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cefazolin, Bacitracin, Cefalexin","genericName":"Cefazolin, Bacitracin, Cefalexin","companyName":"Population Health Research Institute","companyId":"population-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (specific indication unclear from phase 3 context).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}